Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD

類似資料

• Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
  著者:: Tashkin, Donald P, 等
  出版事項: (2012)
• Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials
  著者:: Tashkin, Donald P, 等
  出版事項: (2012)
• Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
  著者:: Kosoglou T, 等
  出版事項: (2013-03-01)
• Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
  著者:: Kosoglou, Teddy, 等
  出版事項: (2013)
• Efficacy and safety of mometasone furoate/formoterol combination in patients with bronchial asthma
  著者:: A. V. Emelyanov
  出版事項: (2015-12-01)